RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)

Participants will receive ivabradine for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months).

"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months)."

Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.

Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.